# SeaBeLife

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/seabelife

- Industry: Biotechnology
- Headquarters: Roscoff, France
- Website: www.seabelife.com
- Total disclosed funding: $2.5M
- Latest round: Seed (Sep 26, 2023)
- Investors on record: 6

## About

Founded in 2019 and based in Roscoff, France, SeaBeLife operates as a biotechnology company that develops families of patented candidate molecules.The company was founded by its CEO, Morgane Rousselot, Stéphane Bach, Marie-Thérèse Dimanche-Boitrel, and CTO, Claire Delehouzé. In October 2025, SeaBeLife raised EUR 2 million in pre-series A funding led by returning investor iXLife Capital, with participation from new investors INEXT and Femmes Business Angels. Other unspecified investors also participated in the round.

SeaBeLife develops patentable candidate compounds to cure necroptosis and ferroptosis, two types of cell death diseases, by deprogramming controlled cell death in the patient to protect or regenerate organs damaged by pathologies. This is accomplished by preventing regulated necrosis (i.e., regulated cell death), which is the primary cause of disorders affecting major organs such as the acute liver (acute hepatic failure) and kidney (acute renal failure). The company conducts research on degenerative and ocular disorders (Parkinson's disease, AMD, and so on) as of 2022.

The company will use the October 2025 funding to develop treatments for dry age-related macular degeneration and severe acute hepatitis.

## Funding rounds

- Seed, Sep 26, 2023, $1.3M — Breizh Angels, WeLikeStartup SAS, Angels Santé, BAdGE et Grenoble Angels, iXLife Capital
- Seed, May 27, 2021, $1.2M — Ava Capital

## Investors

- Ava Capital (https://capitalatlas.ai/funds/ava-capital) — Seed
- Breizh Angels — Seed
- WeLikeStartup SAS — Seed
- Angels Santé (https://capitalatlas.ai/funds/angels-sante) — Seed
- BAdGE et Grenoble Angels — Seed
- iXLife Capital — Seed